YM Biosciences investment case centers on CYT387; analysts view
The oral JAK1/2 inhibitor CYT387 has emerged as Canada-based YM BioSciences’ (TSX: YM) lead development project, having been acquired through last year’s takeover of the Australian biotech company Cytopia, say analysts at Edison Investment Research.
Three significant deals involving competing JAK inhibitors have been struck in the past 18 months or so - showing big pharma’s growing interest in the JAK inhibitor mechanism - and CYT387 is one of the most advanced unpartnered projects in development. It is also the only one to have shown a significant response rate in anemia in myelofibrosis, which could help to differentiate it from competitors.
ASCO presentations underscore potential
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze